UPDATE: Stifel Nicolaus Raises PT to $38 on Align Technology on Trial Outlook
Stifel Nicolaus reiterated its Buy rating on Align Technology (NASDAQ: ALGN) and raised the price target from $32.00 to $38.00.
Stifel Nicolaus said, "Align's patent infringement trial against ClearCorrect is scheduled to begin today. … With the limited information contained in the public filings, Mr. Lavelle acknowledged it would be difficult to handicap the potential outcome of the trial. That said, he seems to think Align has a strong position, given the broad claims covered by the seven patents being asserted against ClearCorrect as well as Align's prior success with some of these same patents in prior litigation with OrthoClear. Additionally, two of the seven patents were recently re-validated by the United States Patent and Trademark Office (USPTO), which likely mitigates ClearCorrect's ability to claim the patents are invalid."
Align Technology closed at $31.90 on Friday.
Latest Ratings for ALGN
|Jul 2016||Stifel Nicolaus||Maintains||Buy|
|May 2016||Credit Suisse||Initiates Coverage on||Outperform|
|Mar 2016||Roth Capital||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.